High grade astrocytic tumor

Summary

High grade astrocytic tumor (MONDO:0016680) is a cancer and 1 clinical trial. Top therapeutic interventions include pembrolizumab and efineptakin alfa. A subtype of astrocytic tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	high grade astrocytic tumor
Mondo ID	MONDO:0016680
Orphanet	251561
NCIT	C102897
UMLS	C3640999
MedGen	769639
GARD	0020704
Is cancer (heuristic)	yes

Also known as: high grade astrocytic neoplasm · high grade astrocytic tumor · high-grade astrocytic neoplasm · high-grade astrocytic tumor · high-grade astrocytic tumour

Disease family

This is a subtype of astrocytic tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › astrocytic tumor › high grade astrocytic tumor

Related subtypes (7): adult astrocytic tumor, childhood astrocytic tumor, gliofibroma, astrocytoma (excluding glioblastoma), low grade astrocytic tumor, anaplastic pleomorphic xanthoastrocytoma, infant-type hemispheric glioma

Subtypes (3): gliomatosis cerebri, anaplastic astrocytoma, glioblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05465954	PHASE2	RECRUITING	Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PEMBROLIZUMAB	4	1
EFINEPTAKIN ALFA	2	1